ALLOGENE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.89 USD | +1.23% |
|
-16.71% | -9.97% |
| Sales 2024 * | 42.75K 3.56M | Sales 2025 * | 4.12M 343M | Capitalization | 493M 41.14B |
|---|---|---|---|---|---|
| Net income 2024 * | -283M -23.6B | Net income 2025 * | -305M -25.43B | EV / Sales 2024 * | 5,693 x |
| Net cash position 2024 * | 250M 20.84B | Net cash position 2025 * | 284M 23.68B | EV / Sales 2025 * | 50.9 x |
| P/E ratio 2024 * |
-1.72
x | P/E ratio 2025 * |
-1.74
x | Employees | 233 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Allogene Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | +1.23% | ||
| 1 week | -16.71% | ||
| Current month | -35.35% | ||
| 1 month | -31.35% | ||
| 3 months | -10.80% | ||
| 6 months | +9.47% | ||
| Current year | -9.97% |
1 week
2.75
3.63
1 month
2.754.58
Current year
2.615.78
1 year
2.236.89
3 years
2.2335.33
5 years
2.2355.00
10 years
2.2355.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joshua Kazam
FOU | Founder | 47 | 01/17/01 |
David Chang
FOU | Founder | 64 | 01/18/01 |
Geoffrey Parker
DFI | Director of Finance/CFO | 59 | 16/23/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Bonderman
BRD | Director/Board Member | 81 | 01/18/01 |
Joshua Kazam
FOU | Founder | 47 | 01/17/01 |
Arie Belldegrun
FOU | Founder | 74 | 01/17/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.54% | 2 M€ | -25.75% | ||
| 0.08% | 0 M€ | 0.00% | - | |
| 0.06% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 2.89 | +1.23% | 2,452,436 |
| 25/24/25 | 2.855 | -6.09% | 2,772,870 |
| 24/24/24 | 3.04 | -9.79% | 2,108,440 |
| 23/24/23 | 3.37 | -0.88% | 1,606,762 |
| 22/24/22 | 3.4 | -2.02% | 1,789,993 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
Calendar
01/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
2.89
USD
Average target price
11.66
USD
Spread / Average Target
+303.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.97% | 493M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ALLO Stock
